Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. BROCADE3 was a randomized, double-blind, placebo-controlled, phase 3 trial done at 147 hospitals in 36 countries. Median progression-free survival was 14.5 months in the veliparib group versus 12.6 months in a control group.
